Monday, August 29, 2016 4:24:57 PM
LENOIR CITY, Tenn. , Aug. 29, 2016 /PRNewswire/ -- Advanced Plasma Products, Inc. (APP) announced today that it is nearing completion of the SBIR Phase II grant provided by the National Institute of General Medical Sciences of the National Institutes of Health . The multi-year grant award total is $2.2 million dollars and focused on the development and testing of the Atmospheric Plasma Wound Applicator (APWA) device to treat chronic wounds which are difficult to treat, generally taking months to years to treat with an expected 50 million cases annually.
APP and its partners from the Center for Biofilm Engineering at Montana State University , the University Of Tennessee Health Science Center College Of Medicine – Knoxville , Graduate School of Medicine , (UTHSCCOM-GSM) and the College of Veterinary Medicine of The University of Tennessee are working on the project to demonstrate disinfection of biofilm infection within a chronic wound.
"We're excited to work with Advanced Plasma Products, Inc. and to apply a new value-based model to medical innovation. Rather than just developing the technology and hoping it will have value in the market, we are looking at a value-based development plan together to see if the technology can decrease costs at the same time as it contributes to improved outcomes and patient satisfaction for definable wound patient groups. The potential value of this technology is to decrease costs with shortened wound healing times and less negative experience (less/no pain, shorter duration of treatment, etc.) for the patient. These value-based outcomes will be considered throughout the development process," said Bruce Ramshaw , MD, FACS, Chair of Surgery at The University of Tennessee Medical Center and UTHSCCOM-GSM.
The company intends to continue developing the APWA device working closely with the UTHSCCOM-GSM. Testing will include toxicity studies and further demonstration of disinfection and wound healing with additional in vivo animal models.
Upon a successful outcome, APP plans to prepare an IRB protocol in collaboration with UTHSCCOM-GSM for treating venous leg ulcers. Chronic venous disease is the most common cause of lower extremity ulcers occurring in 70% to 90% of leg ulcer cases. If the IRB is approved, a small number of patients will be selected for treatment at The University of Tennessee Medical Center .
Research reported in this press release was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number R44GM099207. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health .
About Advanced Plasma Products, Inc.
Advanced Plasma Products, Inc. is an engineering and applied research company with expertise in developing atmospheric plasma products primarily for the healthcare and agricultural sector. It is a wholly owned subsidiary of Applied Science Products (OTC: APLD). The company plans to give further updates in the future as milestones are met. Additionally, the company plans to provide updated financial information in the coming months as well as additional investor information on its website at www.advancedplasmaproducts.com
About UTHSCCOM-GSM and The University of Tennessee Medical Center
Together, The University of Tennessee Medical Center and University of Tennessee Health Science Center College of Medicine – Knoxville , Graduate School of Medicine comprise the only academic medical center in East Tennessee . As an academic medical center, it is developing a value-based model for patient care, education and discovery. Utilizing the principles of value-based clinical quality improvement across the entire cycle of care for definable patient processes, the medical center will help lead the transformation from a healthcare system based on volume to one based on value.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.
CONTACT: Kimberly Kelly-Wintenberg , 1-865-317-1425, info@advancedplasmaproducts.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/advanced-plasma-products-inc-announces-further-development-of-its-atmospheric-plasma-wound-treatment-device-300319524.html
Recent APLD News
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 09/20/2024 09:15:14 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/13/2024 09:06:14 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/11/2024 09:21:04 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/11/2024 08:17:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 10:15:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 12:06:48 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/05/2024 08:26:46 PM
- Applied Digital Announces $160 Million Strategic Financing, Fueling Transformative Accelerated Compute and AI Infrastructure • GlobeNewswire Inc. • 09/05/2024 01:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/04/2024 11:58:21 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/31/2024 01:46:58 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 09:25:19 PM
- Applied Digital Issues $53.2 Million Convertible Preferred Stock to Advance HPC Data Center Project and Accelerate Growth • GlobeNewswire Inc. • 08/30/2024 08:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/30/2024 11:03:36 AM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 08/30/2024 10:53:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 09:08:07 PM
- Applied Digital Reports Fiscal Fourth Quarter and Full Year 2024 Results • GlobeNewswire Inc. • 08/28/2024 08:15:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:18:49 PM
- Applied Digital Strengthens Security Leadership with Appointment of Industry Veteran Gary Smith • GlobeNewswire Inc. • 08/14/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 01:53:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 01:27:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 01:26:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 01:23:55 AM
- Applied Digital Sets Fiscal Fourth Quarter and Full Year 2024 Conference Call for Wednesday, August 28, 2024, at 5:00 p.m. Eastern Time • GlobeNewswire Inc. • 08/07/2024 08:05:00 PM
- Applied Digital Secures Final $25 Million from Garden City Facility Sale • GlobeNewswire Inc. • 07/30/2024 08:40:40 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM